Wondering if GSK is actually undervalued or if there's more to the story than recent headlines suggest? You're not alone, and we're about to dive into what those numbers really mean. Despite a slight ...

GSK PLC (GSK) reports robust sales growth and upgrades its full-year guidance, driven by strong performance in specialty ...

The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).

India's GlaxoSmithKline Pharmaceuticals reported slightly higher second-quarter profit on Thursday, led by steady demand for ...

Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40-billion-pound sales projection ...

GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. | GSK once dreamed of ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

GSK Pharma share price fell 3 per cent after it reported a lower-than-expected top-line for the second quarter of the current ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on GlaxoSmithKline, with a price target of £16.00. The company’s shares opened today at p1,765.00. Take ...

--GSK has lately posted lower vaccine sales in China and the U.S., and faces pressure to show that its pipeline includes new blockbuster drugs to counter concerns about that slowdown, AJ Bell ...

With GSK’s consumer healthcare spinoff now in the rearview mirror, the company is operating as the lean, innovative medicines-focused drugmaker CEO Emma Walmsley envisioned years ago (PDF). And 2022’s ...

Jefferies analyst Michael Leuchten reiterated a Buy rating on GlaxoSmithKline today and set a price target of p2,100.00. The company’s shares closed today at p1,757.00. Take advantage of TipRanks ...